CIITA Gene Bare Lymphocyte Syndrome Type 2 Complementation Group A NGS Genetic DNA Test
Comprehensive Genetic Testing for Immunodeficiency Disorders
The CIITA Gene Bare Lymphocyte Syndrome Type 2 Complementation Group A NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying rare immunodeficiency disorders. This specialized genetic test utilizes next-generation sequencing technology to detect mutations in the CIITA gene, which plays a critical role in immune system regulation and function.
What This Test Measures and Detects
This advanced genetic test specifically targets the CIITA (Class II Major Histocompatibility Complex Transactivator) gene, which is essential for proper immune system development and function. The test identifies:
- Pathogenic variants in the CIITA gene associated with Bare Lymphocyte Syndrome Type 2
- Single nucleotide polymorphisms (SNPs) affecting immune response
- Deletions, insertions, and other structural variations in the genetic sequence
- Mutations that disrupt MHC class II molecule expression
Who Should Consider This Test
This genetic test is particularly important for individuals presenting with:
- Recurrent and severe bacterial, viral, or fungal infections
- Failure to thrive in infancy or childhood
- Autoimmune manifestations and chronic inflammation
- Family history of immunodeficiency disorders
- Unexplained susceptibility to opportunistic infections
- Abnormal lymphocyte counts or function
- Delayed diagnosis despite extensive medical evaluation
Clinical Benefits of Genetic Testing
Undergoing the CIITA gene test provides numerous clinical advantages:
- Accurate Diagnosis: Confirms or rules out Bare Lymphocyte Syndrome Type 2
- Personalized Treatment: Enables targeted therapeutic approaches
- Family Planning: Provides crucial information for genetic counseling
- Early Intervention: Facilitates prompt management of immunodeficiency
- Prognostic Information: Helps predict disease progression and outcomes
- Research Contribution: Advances understanding of rare immunological disorders
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our expert geneticists and immunologists:
- Positive Result: Indicates the presence of pathogenic CIITA gene mutations associated with Bare Lymphocyte Syndrome Type 2
- Negative Result: Suggests no detectable mutations in the tested regions of the CIITA gene
- Variant of Uncertain Significance: Identifies genetic changes with unknown clinical impact requiring further evaluation
- Carrier Status: Determines if you carry one copy of a mutated gene without showing symptoms
All results include comprehensive interpretation and recommendations for next steps in clinical management.
Test Pricing Information
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take Control of Your Health Today
Don’t let uncertainty about your immune health continue. Our CIITA Gene Bare Lymphocyte Syndrome Type 2 NGS Genetic DNA Test provides the clarity you need for proper diagnosis and treatment planning. With results delivered in just 3-4 weeks and sample collection options including blood, extracted DNA, or a simple blood drop on FTA card, getting tested has never been more convenient.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic test consultation and take the first step toward understanding your immunological health.
